As of June 4, 2025, Clinigen Group PLC (CLIN.L) reports a ROA (Return on Assets) of 2.84%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Clinigen Group PLC's ROA (Return on Assets)
Over recent years, Clinigen Group PLC's ROA (Return on Assets) has shown significant volatility. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2021-06-30 | 2.84% |
| 2020-06-30 | 1.20% |
| 2019-06-30 | 0.49% |
| 2018-06-30 | 4.11% |
| 2017-06-30 | 14.34% |
This slight upward trend highlights how Clinigen Group PLC manages its efficiency in using assets to generate earnings over time.
Comparing Clinigen Group PLC's ROA (Return on Assets) to Peers
To better understand Clinigen Group PLC's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Clinigen Group PLC (CLIN.L) | 2.84% |
| Chemometec A/S (CHEMM.CO) | 20.14% |
| Ergomed PLC (ERGO.L) | 11.58% |
| MedCap AB (publ) (MCAP.ST) | 10.41% |
| Genovis AB (GENO.ST) | 10.05% |
| Eurofins-Cerep SA (ALECR.PA) | 9.67% |
Compared to its competitors, Clinigen Group PLC's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.